BLC
TMO icon

Blue Line Capital’s Thermo Fisher Scientific TMO Stock Holding History

Blue Line Capital’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,710
Closed -$841K – 96
2026
Q1 		$841K Buy
1,710
+132
+8% +$71.6K 0.95% 38
2025
Q4 		$914K Buy
+1,578
New +$892K 1.08% 32

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Blue Line Capital's TMO Position: Q2 2026 in Review

Blue Line Capital sold out of Thermo Fisher Scientific (TMO) in Q2 2026, closing a stake of 1,710 shares — an estimated $841K sold.

Blue Line Capital first reported a position in TMO in Q4 2025 and held it in 2 quarters. The position peaked at $914K in Q4 2025. 2,613 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Blue Line Capital reported no remaining Thermo Fisher Scientific position as of Q2 2026 after selling out during the quarter.
  • Blue Line Capital sold 1,710 Thermo Fisher Scientific shares in Q2 2026, an estimated $841K.
  • Blue Line Capital first reported a position in Thermo Fisher Scientific in Q4 2025 and held it in 2 quarters.
  • Blue Line Capital's Thermo Fisher Scientific position peaked at $914K in Q4 2025.
  • 2,613 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Blue Line Capital's 13F filing for Q2 2026, filed 30 Jul 2026.